验证用于局部晚期肺癌自适应放疗的肿瘤缩小预测图谱
本研究利用两家独立机构共34例患者数据交叉验证并扩展了一个预测放疗期间肺部肿瘤几何缩小模式的图谱,并构建贝叶斯方法利用疗程中影像校正预测。预测准确率跨机构相当(0.71对0.73),扩展图谱后提升至0.74,校正后进一步提升至0.76。回顾性预测治疗计划研究显示,与自适应放疗相比,预测治疗计划使实际残留肿瘤的平均剂量平均增加6.3Gy。
要点
- 预测图谱跨机构预测准确率相当,扩展至34例后准确率提升至0.74。
- 贝叶斯校正后预测准确率进一步提升至0.76。
- 预测治疗计划使残留肿瘤平均剂量较自适应放疗增加6.3Gy。
核心结论
- 预测图谱跨机构表现良好,并受益于更多样化的缩小模式和肿瘤位置。
- 在整个疗程中将杀肿瘤剂量提升至预测的残留肿瘤,可能较疗程中重新规划的自适应放疗改善疗效和效率。
研究设计与样本
- 研究纳入合作机构22例患者数据,用于交叉验证最初由12例患者创建的预测图谱。
- 随后整合全部34例患者数据以扩展图谱,每例研究患者通过留一法方案选取,并基于肿瘤体积和周围环境的相似性度量与其余33例患者中的亚组匹配。
- 通过阈值化亚组中叠加的缩小模式来估计残留肿瘤的空间分布,并开发贝叶斯方法利用疗程中影像观察到的肿瘤重新校准预测。
- 在回顾性预测治疗计划研究中,于初始计划阶段将预测的残留肿瘤剂量提升至最高可达到剂量,同时维持肿瘤其余部分的原处方剂量,并将预测治疗计划与利用疗程中影像重新规划的自适应放疗以及使用重新校准预测的预测治疗计划-自适应放疗进行等毒性比较。
主要发现
- 基于预测与实际残留肿瘤的真阳性加真阴性比率,预测准确率跨机构相当,为0.71对0.73。
- 扩展图谱纳入两家机构后,预测准确率提升至0.74。
- 重新校准进一步将准确率提升至0.76。
- 与自适应放疗相比,预测治疗计划使实际残留肿瘤的平均剂量平均增加6.3Gy。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To cross-validate and expand a predictive atlas that can estimate geometric patterns of lung tumor shrinkage during radiation therapy using data from 2 independent institutions and to model its integration into adaptive radiation therapy (ART) for enhanced dose escalation. METHODS AND MATERIALS: Data from 22 patients at a collaborating institution were obtained to cross-validate an atlas, originally created with 12 patients, for predicting patterns of tumor shrinkage during radiation therapy. Subsequently, the atlas was expanded by integrating all 34 patients. Each study patient was selected via a leave-one-out scheme and was matched with a subgroup of the remaining 33 patients based on similarity measures of tumor volume and surroundings. The spatial distribution of residual tumor was estimated by thresholding the superimposed shrinkage patterns in the subgroup. A Bayesian method was also developed to recalibrate the prediction using the tumor observed on the midcourse images. Finally, in a retrospective predictive treatment planning (PTP) study, at the initial planning stage, the predicted residual tumors were escalated to the highest achievable dose while maintaining the original prescription dose to the remainder of the tumor. The PTP approach was compared isotoxically to ART that replans with midcourse imaging and to PTP-ART with the recalibrated prediction. RESULTS: Predictive accuracy (true positive plus true negative ratios based on predicted and actual residual tumor) were comparable across institutions, 0.71 versus 0.73, and improved to 0.74 with an expanded atlas including 2 institutions. Recalibration further improved accuracy to 0.76. PTP increased the mean dose to the actual residual tumor by an averaged 6.3Gy compared to ART. CONCLUSION: A predictive atlas found to perform well across institutions and benefit from more diversified shrinkage patterns and tumor locations. Elevating tumoricidal dose to the predicted residual tumor throughout the entire treatment course could improve the efficacy and efficiency of treatment compared to ART with midcourse replanning.
引用
- Zhang P, Yorke E, Mageras G, et al. Validating a Predictive Atlas of Tumor Shrinkage for Adaptive Radiotherapy of Locally Advanced Lung Cancer. Int J Radiat Oncol Biol Phys. 2018. PMID: 30061006. doi:10.1016/j.ijrobp.2018.05.056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。